| Jacob Robert Fenster, | |
|
5001 Hardy St, Hattiesburg, MS 39402-1308 | |
| (601) 296-3963 | |
| Not Available |
| Full Name | Jacob Robert Fenster |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 7 Years |
| Location | 5001 Hardy St, Hattiesburg, Mississippi |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134668189 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | WILL APPLY (Mississippi) | Secondary |
| 207P00000X | Emergency Medicine | 036156624 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Blessing Hospital | Quincy, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Blessing Hospital | 3072422534 | 345 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.
Another benefit of rapid weight loss after bariatric surgery is a 50 percent reduction in use of prescription breathing medications, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).
Marlborough, Mass. Boston Scientific Corporation today announced the European launch of the LithoVue Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to diagnose and treat stones and other conditions of the kidney, ureter and bladder.
› Verified 9 days ago
| Entity Name | Blessing Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255515342 PECOS PAC ID: 3072422534 Enrollment ID: O20040330001155 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.
Another benefit of rapid weight loss after bariatric surgery is a 50 percent reduction in use of prescription breathing medications, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).
Marlborough, Mass. Boston Scientific Corporation today announced the European launch of the LithoVue Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to diagnose and treat stones and other conditions of the kidney, ureter and bladder.
› Verified 9 days ago
| Entity Name | Blessingcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992038640 PECOS PAC ID: 2769420959 Enrollment ID: O20050419000684 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.
Another benefit of rapid weight loss after bariatric surgery is a 50 percent reduction in use of prescription breathing medications, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).
Marlborough, Mass. Boston Scientific Corporation today announced the European launch of the LithoVue Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to diagnose and treat stones and other conditions of the kidney, ureter and bladder.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jacob Robert Fenster, 1005 Broadway St, Quincy, IL 62301-2834 Ph: (217) 223-8400 | Jacob Robert Fenster, 5001 Hardy St, Hattiesburg, MS 39402-1308 Ph: (601) 296-3963 |
News Archive
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company's two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-d) met both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) formally agreed-upon primary endpoints of composite response based on simultaneous improvements in stool consistency and abdominal pain.
Research led by Dr. Carlos Arteaga, Director of the Harold C. Simmons Comprehensive Cancer Center, has identified potential targets for treatment of triple negative breast cancer, the most aggressive form of breast cancer.
Another benefit of rapid weight loss after bariatric surgery is a 50 percent reduction in use of prescription breathing medications, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).
Marlborough, Mass. Boston Scientific Corporation today announced the European launch of the LithoVue Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to diagnose and treat stones and other conditions of the kidney, ureter and bladder.
› Verified 9 days ago
Bradley Williams, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 601-296-3963 | |
Miju Yu Kurtzweil, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5001 Hardy St, Merit Health Wesley, Hattiesburg, MS 39402 Phone: 601-296-3963 | |
Dr. Carl Edward Johns Iii, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5001 Hardy St, Hattiesburg, MS 39402 Phone: 601-296-3963 | |
Robert C Owen, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6051 Highway 49, Hattiesburg, MS 39401 Phone: 601-288-7000 | |
Trent Woods, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6051 Highway 49, Hattiesburg, MS 39401 Phone: 601-288-7000 | |
Julie Marie Butler, ATC Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 118 College Dr, Hattiesburg, MS 39406 Phone: 601-268-5017 |